MP 3549.1

Drug Profile

MP 3549.1

Alternative Names: MNK010; MP-3549-1; MP-3549.1

Latest Information Update: 09 Jun 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mallinckrodt Inc.
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 31 May 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 18 May 2016 No recent reports on development identified - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 31 Jul 2013 Phase-I clinical trials in Solid tumours (late-stage disease, second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top